Skip to contentN
NovoCure Ltd
N
NVCRNovoCure Ltd Q4 2021 · 10-K
Revenue$133.21M$133.21M−7.5% vs Q4 2020 Net Income-$26.46M-$26.46MN/M vs Q4 2020 EPS Diluted-$0.25-$0.25N/M vs Q4 2020 Gross Profit$103,526,000−10.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR
Operating Cash Flowderived$14,404,000−73.1% Free Cash Flowderived$130,000−99.7% Margins · derivedGross margin77.7%−2.7 pt vs Q4 2020
Operating margin-17.6%−26.0 pt vs Q4 2020
Net margin-19.9%−23.3 pt vs Q4 2020
ended Dec 31, 2021 · filed Feb 24, 2022 · 55 d after period end